An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT).

Trial Profile

An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT).

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Ustekinumab (Primary) ; Methotrexate
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms TRANSIT
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 07 Nov 2012 Quality of life outcomes presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 28 Sep 2012 Results were presented at the 21st European Academy of Dermatology and Venereology (EADV) congress in late September 2012.
    • 16 Nov 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top